NeRRe Therapeutics is a clinical-stage company specializing in the development of the neurokinin (NK)-1 receptor antagonist known as orvepitant. Their focus is on providing effective treatment for common, chronic, and debilitating conditions caused by neural hypersensitivity associated with Substance P/ NK-1 receptor system dysfunction. One of their main objectives is to address the disabling chronic cough associated with the rare and terminal lung disease idiopathic pulmonary fibrosis (IPF), which currently lacks approved treatments.

Through their Phase 2b study (VOLCANO-2), NeRRe Therapeutics has demonstrated the efficacy of orvepitant 30 mg once daily in significantly improving cough burden in patients with refractory or unexplained chronic cough (RUCC). While the study did not show a significant effect on cough frequency as a whole, it did indicate positive outcomes for subjects with higher cough frequencies at baseline. NeRRe Therapeutics is currently evaluating orvepitant as a potential treatment for chronic cough in IPF patients, who urgently require effective therapies for their condition.

To learn more about NeRRe Therapeutics, you can get to know the dedicated team behind their successes